Clinical trials: Haemodialyzed, Type 2 Diabetes
Haemodialyzed, Type 2 Diabetes
A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM
Diabetes is a major concern for dialysis units, as it is now the most common cause of end-stage renal disease in France. In 2010 at initiation of dialysis treatment, more than one patient out of two had at least one…
- Trial name
- NCT02176681
- Testing
- Vildagliptin (Galvus), Insulin
- Where
- 13 sites in France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Strasbourg, France